ZILBRYSQ ZILUCOPLAN
Dead / Abandoned — Abandoned — no statement of use filed (as of 28 Jun 2021)
What this means for you
This application is over — abandoned 28 Jun 2021. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 88918443
- Mark type
- Word mark
- Filed
- 15 May 2020
- Published for opposition
- 29 Sept 2020
- Abandoned
- 28 Jun 2021
- Attorney of record
- Jennifer Bryan
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations, for human use, for the prevention and treatment of paroxysmal nocturnal hemoglobinuria, myasthenia gravis, an inflammatory disorder, a wound, a burn, an autoimmune disorder, a pulmonary disorder, a cardiovascular disorder, a neurological disorder, a kidney-related disorder, a diabetes-related disorder, an ocular disorder, and a pregnancy-related disorder; Pharmaceutical preparations, for human use, for the prevention and treatment of disorders of metabolism, the nervous system, the immune system, the cardio-vascular system, the respiratory system, the musculo-skeletal system, and the genitourinary system; Pharmaceutical preparations for the treatment of fibrotic and inflammatory disorders; Pharmaceutical preparations for use in dermatology, nephrology, hepatology, rheumatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Pharmaceutical preparations as anti-viral, anti-bacterial, or anti-fungal agents, all of the foregoing containing Zilucoplan
- Class 010 — Medical apparatus: Syringes for injections; Syringes for medical purposes; Syringes for medical purposes sold empty which may be filled with pharmaceutical preparations, for human use, for the prevention and treatment of paroxysmal nocturnal hemoglobinuria, myasthenia gravis, an inflammatory indication, a wound, a burn, an autoimmune indication, a pulmonary indication, a cardiovascular indication, a neurological indication, a kidney-related indication, a diabetes-related indication, an ocular indication, and a pregnancy-related indication
Owner
- Ra Pharmaceuticals, Inc., Cambridge, MA, US
- Ra Pharmaceuticals, Inc., Cambridge, MA, US
Prosecution history
- 28 Jun 2021 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 28 Jun 2021 — ABANDONMENT - NO USE STATEMENT FILED
- 24 Nov 2020 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 29 Sept 2020 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 29 Sept 2020 — PUBLISHED FOR OPPOSITION
- 09 Sept 2020 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 08 Sept 2020 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 01 Sept 2020 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 01 Sept 2020 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 01 Sept 2020 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 25 Aug 2020 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 25 Aug 2020 — EXAMINER'S AMENDMENT ENTERED
- 25 Aug 2020 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 25 Aug 2020 — EXAMINERS AMENDMENT E-MAILED
- 25 Aug 2020 — EXAMINERS AMENDMENT -WRITTEN